Get the Stockscreener App
0.8776
3.37%
-0.0306
After Hours:
.876
-0.0016
-0.18%
Why is OptiNose Inc (OPTN) Stock down?
We've noticed a 5.20% decline in OptiNose Inc (OPTN) stock during the 2024-04-30 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
06 Dec, 2023:
Shares of OptiNose Inc (OPTN) dropped by 16.33% from $1.47 to $1.23 in the trading on Wednesday, December 6, 2023. The reason why OPTN is down today is due to the announcement that the U.S. Food and Drug Administration (FDA) has extended the review period for the company's supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis. The new Prescription Drug User Fee Act (PDUFA) goal date for the review is March 16, 2024. The FDA's decision to extend the review period for XHANCE's sNDA has raised uncertainties and delayed potential approval. This extension likely led to concerns among investors, resulting in the notable drop in the stock price.
2.43%
3.29%
Cap:
|
Volume (24h):